- Home
- RC vs INBX Comparison
RC vs INBX Comparison
Compare RC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RC | INBX |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | 475 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.9M | 1.1B |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | RC | INBX |
|---|---|---|
| Price | $1.89 | $73.67 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $2.81 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 133.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | ★ 649.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $200,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | $67.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.55 | $10.81 |
| 52 Week High | $5.25 | $94.57 |
Technical Indicators
Market Signals| Indicator | RC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 43.81 |
| Support Level | $1.60 | $72.13 |
| Resistance Level | $2.42 | $85.97 |
| Average True Range (ATR) | 0.14 | 4.46 |
| MACD | 0.03 | -0.84 |
| Stochastic Oscillator | 57.50 | 31.20 |
Price Performance
Historical ComparisonAbout RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.